Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immunological characteristics of the leukemia cells transfected with oncostatin M gene by recombinant adenovieus

Abstract

In the present study, FBL-3 murine erythroleukemia cells were transacted with human OSM(hOSM) gene by recombinant adenovirus, then the immunological properties of hOSM gene-transfected FBL-3 cells(FBL-3-OSM+) were investigated. 4 hours after transfection with hOSM gene, hOSM could be detected in the supernatant of FBL-3-OSM+ cells and hOSM secretion peaked at 24 h. The proliferation of FBL-3-OSM+ cells was inhibited markedly. The clonal formation of FBL-3-OSM+ cells was suppressed more obviously in comparison with wild-type FBL-3 cells when analysed in clonal argar culture. Flow cytometry analysis showed that FBL-3-OSM+ cells expressed higher levels of Fas protein, B7 and ICAM-1 molecuIes.FBL-3-OSM+ cells also expressed higher level of MHC class I molecules(H-2Kb) but remained unchanged in expression of MHC class II molecules (la). CD14, which is a specific marker of monocyte/macrophage and not expressed on the wild-type FBL-3 cells, was also detected on the surface of FBL-3-OSM+ cells. The results suggested that OSM gene transfer could increase the immunogenicity of FBL-3 cells and promote their differentiation into macrophage-like cells. The data outline a promising approach to OSM gene therapy of leukemia mediated by recombinant adenovirus.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Rose TM and Bruce AG. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci USA 1991; 88:8641.

  2. 2.

    Wallace PM, Macmaster JF, Rillema JR, et al. In vivo properties of oncostatin M. Ann N Y Acad Sci 1995; 762:42.

  3. 3.

    Bruce AG, Hoggatt IH, Rose TM. et al. Oncostatin M is a differentiation factor for myeloid leukemia cells. J Immunol 1992; 149:1271.

  4. 4.

    Yoshida Y. and Hamada H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun 1997; 230:426.

  5. 5.

    Naemura JR and Radka SF. Detection of oncostatin M in human plasma and serum by a sensitive enzyme immunoassay. Lymphokine Cytokine Res 1993; 12:187.

  6. 6.

    Tanigawa T, Nicola N, McArthur GA, et al. Differential regulation of macrophage differentiation in response to leukemia inhibitory factor/oncostatin-M/interleukin-6: the effect of enforced expression of the SCL transcription factor. Blood 1995; 85:379.

  7. 7.

    Wallace PM, MacMaster JF, Rillema JR, et al. Thrombocytopoietic properties of oncostatin M. Blood 1995; 86:1310.

  8. 8.

    Clegg CH, Rulffes JT, Wallace PM, et al. Regulation of an extrathymic T-cell development pathway by oncostatin M. Nature 1996; 384:261.

  9. 9.

    Kaneda R, Iweabuchi K and Onoe K. Dissociation of Fas-mediated cytotoxicity and FasL expression in a cytotoxic CD4+ T cell clone. Immunol Lett 1997; 55:53.

Download references

Author information

Correspondence to Xuetao Cao.

Additional information

This work was supported by the National Natural Science Foundation of China (No. 39421009).

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wang, Q., Cao, X., Mi, J. et al. Immunological characteristics of the leukemia cells transfected with oncostatin M gene by recombinant adenovieus. Chin J Cancer Res 9, 272–276 (1997). https://doi.org/10.1007/BF02974973

Download citation

Key words

  • Oncostatin M
  • Gene transfer
  • Erythroleukemia
  • Immunogenicity
  • Costimulatory molecules
  • CD14